Open Access Articles

Drug Supply Chain Management in COVID-19 Pandemic:Lessons from Iran and Preparation for Future

Authors

  • Younes Nobakht * Department of Management and accounting, Faculty of Humanities and Arts, Technical and Vocational University (TVU), Tehran, Iran

https://doi.org/10.22105/raise.vi.72

Abstract

The COVID-19 pandemic has caused unprecedented challenges to all nations worldwide. Among these challenges, a drug shortage can have adverse effects on the health of the world community. This paper in the evaluation of drug supply chain management during the COVID-19 pandemic focuses on the potential resources of drug shortage, initial preparation, and plans for eliminating probable shortages and improving Iran’s drug supply chain management The paper also makes some evidence-based suggestions to ensure the accessibility of drugs and improvement in drug supply chain management both during a pandemic and in the long run. Everyone involved in the supply chain needs to cooperate in a bid to achieve preparation and formulate transparent emergency plans to deal with the drug shortage caused by the COVID-19 pandemic. Therefore, it is essential to revise and improve supply chain management strategies, ensure transparent information, adopt active management, and maintain timely and comprehensive communication to sustain drug supply during a disease outbreak. In addition, raising public awareness of drug shortages, confronting misinformation, and providing timely responses to public opinion are among the factors that should be considered.

Keywords

Supply chain management Drug supply chain Production Pandemic Drug shortage
References (11)
  1. [1] Kuo, S., Ou, H. T., & Wang, C. J. (2021). Managing medication supply chains: Lessons learned from Taiwan during the COVID-19 pandemic and preparedness planning for the future. Journal of the american pharmacists association, 61(1), e12--e15. https://doi.org/10.1016/j.japh.2020.08.029

  2. [2] Jahangiri, S., Abolghasemian, M., Ghasemi, P., & Chobar, A. P. (2023). Simulation-based optimisation: analysis of the emergency department resources under COVID-19 conditions. International journal of industrial and systems engineering, 43(1), 1–19. https://doi.org/10.1504/IJISE.2023.128399

  3. [3] Horner, R. (2020). The world needs pharmaceuticals from China and India to beat coronavirus. The conversation, 25. https://www.telegraph.co.uk/global-health/science-and-disease/world-needs-pharmaceuticals-china-india-beat-coronavirus/

  4. [4] Olyaaeemanesh, A., Jaafaripooyan, E., Abdollahiasl, A., Davari, M., Mousavi, S. M., & Delpasand, M. (2021). Pharmaceutical subsidy policy in Iran: a qualitative stakeholder analysis. Health research policy and systems, 19(1), 150. https://doi.org/10.1186/s12961-021-00762-6

  5. [5] Cheraghali, A. M. (2013). Impacts of international sanctions on Iranian pharmaceutical market. DARU journal of pharmaceutical sciences, 21(1), 64. https://doi.org/10.1186/2008-2231-21-64

Article Metrics

How to Cite

Nobakht, Y. (2025). Drug Supply Chain Management in COVID-19 Pandemic:Lessons from Iran and Preparation for Future. Research Annals of Industrial and Systems Engineering, 2(3), 190-195. https://doi.org/10.22105/raise.vi.72

Similar Articles

1-10 of 39

You may also start an advanced similarity search for this article.